Hypertriglyceridemia - Pipeline Insight, 2024

This “Hypertriglyceridemia- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypertriglyceridemia: Understanding

Hypertriglyceridemia: Overview

Hypertriglyceridemia (HTG) is a common clinical condition most often identified in individuals who have had a lipid profile as part of cardiovascular risk assessment. HTG may be primary or secondary in nature. Primary HTG is the result of various genetic defects leading to disordered triglyceride metabolism. Secondary causes are acquired causes, such as, high fat diet, obesity, diabetes, hypothyroidism, and certain medications, all of which are more prevalent in industrialized societies than in developing nations. Based on the Serum triglyceride concentration, HTG can be categorized into mild, moderate, and severe.

Individuals with severe HTG have triglyceride levels more than three times the normal triglycerides level. Severe HTG is well known to be associated with severe diseases such as acute pancreatitis and cardiovascular disease. It occurs from VLDL overproduction and defective triglyceride clearance due to either saturation or dysfunction of the enzyme lipoprotein lipase (LPL), resulting in the accumulation of chylomicrons and VLDLs. Unfortunately, most people with high triglyceride levels don’t experience symptoms. This is why it’s important to get the levels tested if patient have a family history of heart disease, stroke, or high triglycerides. However, some people with very high levels of triglycerides may experience symptoms, including upper abdominal pain, xanthomas, creamy white discoloration of the retinal vessels, and irritability. HTG is diagnosed by a fasting lipid panel. According to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, HTG is classified into mild: TG level 150-199 mg/dL, high: TG 200-499 mg/dL and very high: TG > 500 mg/dL. When triglycerides are above 400 mg/dL, LDL-C levels are calculated using the Friedewald equation. Since the calculation can underestimate LDL-C, the alternative is to calculate non-HDL-C levels (total cholesterol minus HDL cholesterol) or obtain direct LDL-C levels if possible. The measurement of LDL size or density is not useful in the management of cardiovascular events. Apo B and Lp (a) may be useful in assessing cardiovascular risk in HTG. There are some effective therapies for lowering Apo B. Treatment
The recommendations of the UK National Institute for Health and Care Excellence (NICE) follow a similar line of reasoning: For patients with hypertriglyceridemia, NICE recommends optimization of the cardiovascular risk profile on the basis of non-HDL-cholesterol, but does not mention concrete target levels. Likewise, the German College of General Practitioners and Family Physicians (DEGAM, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin) points out that the cardiovascular risk is increased in patients with both hypertriglyceridemia and combined hyperlipoproteinemia. Lifestyle modifications are of paramount importance when treating patients with hypertriglyceridemia. The key measures are to avoid alcohol and to significantly reduce the intake of rapidly metabolizable carbohydrates, especially drinks containing sugar. In addition, the intake of animal fats should be restricted. However, there are as yet no cardiovascular endpoint studies demonstrating the benefits of lifestyle modifications. Given the central role of lifestyle changes, patients should be offered the opportunity to receive nutritional counseling.

Hypertriglyceridemia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs

Pegozafermin: 89bioPegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). FGF21 is a promising therapeutic target for NASH and SHTG since it is an endogenous hormone that functions as a master metabolic regulator with broad effects on energy expenditure and glucose and lipid metabolism. Enhancing the activity of FGF21 has been shown to reduce hepatic steatosis, inflammation, and triglyceride levels, as well as improve insulin resistance and glycemic control. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Severe Hypertriglyceridemia.

SEFA-1024: NorthSea TherapeuticsSEFA-1024 is a novel, orally-administered, highly potent, chemically modified fatty acid derived from naturally occurring fatty acid EPA. SEFA-1024 was designed to enhance its pharmacological effects on metabolic markers in the intestine and liver. In pre-clinical dyslipidemia models, SEFA-1024 exhibited broad and marked beneficial effects, significantly reducing both non-HDL cholesterol and triglycerides in conjunction with an increase in HDL cholesterol. The cholesterol-lowering activity of SEFA-1024 was additive to the lowering obtained with statin treatment, suggesting that SEFA-1024 could be used in combination with these important standard-of-care cardiovascular therapies. Further, it was shown that dosing with SEFA-1024 leads to marked improvements in glycemic control, indicating that SEFA-1024 has the potential to improve overall glycemic control in patients with diabetes. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Hypertriglyceridemia.

VSA-003: Visirna TherapeuticsVSA-003, is an investigational drug being developed by Visirna Therapeutics. The drug belongs to the class of Small interfering RNA. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Hypertriglyceridemia.

Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hypertriglyceridemia

There are approx. 20+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, 89bio.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights

• Hypertriglyceridemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypertriglyceridemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypertriglyceridemia drugs?
• How many Hypertriglyceridemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypertriglyceridemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• 89bio
• Mochida Pharmaceutical
• NorthSea Therapeutics
• Visirna Therapeutics
• GeneCradle Therapeutics
• Sirnaomics
• Eli Lilly and Company
• Lipigon Pharmaceuticals
• iMetabolic Biopharma

Key Products

• MND 2119
• Pegozafermin
• SEFA 1024
• VSA003
• GC304
• STP237G
• LY3875383
• Lipisense
• iMBP 150

This product will be delivered within 1-3 business days.